ReviewClinical & developmental immunology2013
Bone effects of biologic drugs in rheumatoid arthritis.
Review in Clinical & developmental immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Gout is not associated with the risk of fracture: a meta-analysis.Journal of orthopaedic surgery and research · 2019Pooled it
- Role of Cytokines in Bone Diseases and Their Therapeutic Application.ImmunoTargets and therapy · 2026Review
- Osteoimmunology: interactions of the bone and immune system.Frontiers in immunology · 2026Review
- Infliximab prevents systemic bone loss and suppresses tendon inflammation in a collagen-induced arthritis rat model.Inflammopharmacology · 2021Article
- IL-23 receptor deficiency results in lower bone mass via indirect regulation of bone formation.Scientific reports · 2021Article
- High susceptibility to collagen-induced arthritis in mice with progesterone receptors selectively inhibited in osteoprogenitor cells.Arthritis research & therapy · 2020Article
- Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review.International journal of oral science · 2020Review
- Molecular mechanisms and clinical management of cancer bone metastasis.Bone research · 2020Review
- Regulation of Osteoclast Differentiation by Cytokine Networks.Immune network · 2018Review
- Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies.Current rheumatology reports · 2016Article
- Article
- NF-κB Has a Direct Role in Inhibiting Bmp- and Wnt-Induced Matrix Protein Expression.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2016Article
- Modeling effects of dexamethasone on disease progression of bone mineral density in collagen-induced arthritic rats.Pharmacology research & perspectives · 2015Article
- Hand bone mass in rheumatoid arthritis: A review of the literature.World journal of orthopedics · 2015Review
- Dietary supplementation with arachidonic acid increases arachidonic acid content in paw, but does not affect arthritis severity or prostaglandin E2 content in rat adjuvant-induced arthritis model.Lipids in health and disease · 2015Article
- A Short Peptide That Mimics the Binding Domain of TGF-β1 Presents Potent Anti-Inflammatory Activity.PloS one · 2015Article
- The role of IL-1β in the bone loss during rheumatic diseases.Mediators of inflammation · 2015Review
- Induction of osteoclast progenitors in inflammatory conditions: key to bone destruction in arthritis.International orthopaedics · 2014Review
- The role of TNF-α and TNF superfamily members in the pathogenesis of calcific aortic valvular disease.TheScientificWorldJournal · 2013Article
- Role of various pharmacologic agents in alveolar bone regeneration: A review.National journal of maxillofacial surgeryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biologic agents used in the treatment of rheumatoid arthritis (RA) are able to reduce both disease activity and radiographic progression of joint disease. These drugs are directed against several proinflammatory cytokines (TNF α , IL-6, and IL-1) which are involved both in the pathogenesis of chronic inflammation and progression of joint structural damage and in systemic and local bone loss typically observed in RA. However, the role of biologic drugs in preventing bone loss in clinical practice has not yet clearly assessed. Many clinical studies showed a trend to a positive effect of biologic agents in preventing systemic bone loss observed in RA. Although the suppression of inflammation is the main goal in the treatment of RA and the anti-inflammatory effects of biologic drugs exert a positive effect on bone metabolism, the exact relationship between the prevention of bone loss and control of inflammation has not been clearly established, and if the available biologic drugs against TNF α , IL-1, and IL-6 can exert their effect on systemic and local bone loss also through a direct mechanism on bone cell metabolism is still to be clearly defined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.